FI3536797T3 - Siirtogeenin tehostettu ilmentäminen ja prosessointi - Google Patents

Siirtogeenin tehostettu ilmentäminen ja prosessointi Download PDF

Info

Publication number
FI3536797T3
FI3536797T3 FIEP19153376.9T FI19153376T FI3536797T3 FI 3536797 T3 FI3536797 T3 FI 3536797T3 FI 19153376 T FI19153376 T FI 19153376T FI 3536797 T3 FI3536797 T3 FI 3536797T3
Authority
FI
Finland
Prior art keywords
mar
transgene
vector
nucleic acid
tep
Prior art date
Application number
FIEP19153376.9T
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Inventor
Fourn Valérie Le
Nicolas Mermod
Alexandre Regamey
Montse Buceta
Déborah Ley
Niamh Harraghy
Kaja Kostyrko
Pierre-Alain Giro
David Calabrese
Original Assignee
Selexis Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Selexis Sa filed Critical Selexis Sa
Application granted granted Critical
Publication of FI3536797T3 publication Critical patent/FI3536797T3/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/90—Vectors containing a transposable element
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/46—Vector systems having a special element relevant for transcription elements influencing chromatin structure, e.g. scaffold/matrix attachment region, methylation free island

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
FIEP19153376.9T 2013-02-01 2014-02-01 Siirtogeenin tehostettu ilmentäminen ja prosessointi FI3536797T3 (fi)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361759802P 2013-02-01 2013-02-01
US201361800244P 2013-03-15 2013-03-15
US201361806634P 2013-03-29 2013-03-29

Publications (1)

Publication Number Publication Date
FI3536797T3 true FI3536797T3 (fi) 2023-03-23

Family

ID=50239688

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP19153376.9T FI3536797T3 (fi) 2013-02-01 2014-02-01 Siirtogeenin tehostettu ilmentäminen ja prosessointi

Country Status (20)

Country Link
US (1) US11898154B2 (enExample)
EP (2) EP2951309B1 (enExample)
JP (1) JP6563816B2 (enExample)
KR (1) KR102235603B1 (enExample)
CN (2) CN120718957A (enExample)
AU (2) AU2014210856B2 (enExample)
CA (1) CA2898878C (enExample)
DK (2) DK2951309T3 (enExample)
ES (2) ES2717175T3 (enExample)
FI (1) FI3536797T3 (enExample)
HU (2) HUE061494T2 (enExample)
IL (1) IL240198B (enExample)
LT (1) LT2951309T (enExample)
PL (2) PL3536797T3 (enExample)
PT (2) PT2951309T (enExample)
RU (1) RU2711505C9 (enExample)
SG (2) SG10201803758XA (enExample)
SI (1) SI2951309T1 (enExample)
WO (1) WO2014118619A2 (enExample)
ZA (1) ZA201506419B (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109576269B (zh) * 2014-04-01 2020-08-28 三生国健药业(上海)股份有限公司 一种含mar核心片段的动物细胞表达载体
CN105154473B (zh) * 2015-09-30 2019-03-01 上海细胞治疗研究院 一种高效安全的转座子整合系统及其用途
US20180265894A1 (en) * 2015-10-06 2018-09-20 National University Corporation Okayama University Gene Expression Cassette And Product Thereof
JP6871679B2 (ja) * 2016-03-23 2021-05-12 国立大学法人 岡山大学 遺伝子発現用カセット及びその産生物
JP2017070224A (ja) * 2015-10-06 2017-04-13 国立大学法人 岡山大学 遺伝子発現用カセット及びその産生物
WO2017109177A1 (en) 2015-12-24 2017-06-29 Selexis S.A. Improved eukaryotic cells for protein manufacturing and methods of making them
ITUA20161610A1 (it) * 2016-03-14 2017-09-14 Angela Anna Messina Composto peptidico farmacologicamente attivo, procedimento per la sua preparazione e suo uso.
EP3219800A1 (en) * 2016-03-15 2017-09-20 Max-Delbrück-Centrum Für Molekulare Medizin A transposon-based transfection system for primary cells
EP3219803A1 (en) * 2016-03-15 2017-09-20 Max-Delbrück-Centrum für Molekulare Medizin Enhanced sleeping beauty transposons, kits and methods of transposition
WO2017191165A1 (en) * 2016-05-03 2017-11-09 Lonza Ltd Modulation of lipid metabolism for protein production
JP7382138B2 (ja) * 2016-10-03 2023-11-16 第一三共株式会社 Hspa5遺伝子のプロモーター
CA3047313A1 (en) 2016-12-16 2018-06-21 B-Mogen Biotechnologies, Inc. Enhanced hat family transposon-mediated gene transfer and associated compositions, systems, and methods
US11278570B2 (en) 2016-12-16 2022-03-22 B-Mogen Biotechnologies, Inc. Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods
WO2018224162A1 (en) * 2017-06-09 2018-12-13 Biontech Rna Pharmaceuticals Gmbh Methods for characterizing loss of antigen presentation
JP7240749B2 (ja) * 2017-09-29 2023-03-16 ベスファジェン・インコーポレイテッド 心不全の予防または治療のための医薬組成物
CN109929839B (zh) * 2017-12-18 2021-02-12 华东师范大学 拆分型单碱基基因编辑系统及其应用
CN108504692B (zh) * 2018-03-26 2021-07-23 安徽大学 一种基因敲除cho细胞株的构建方法及其在治疗性重组蛋白表达中的应用
WO2019219947A1 (en) * 2018-05-18 2019-11-21 Sorbonne Universite Molecular tools and methods for transgene integration and their transposition dependent expression
WO2019246486A2 (en) 2018-06-21 2019-12-26 B-Mogen Biotechnologies, Inc. ENHANCED hAT FAMILY TRANSPOSON-MEDIATED GENE TRANSFER AND ASSOCIATED COMPOSITIONS, SYSTEMS, AND METHODS
RU2686102C1 (ru) * 2018-08-07 2019-04-24 Федеральное Государственное Бюджетное Учреждение Науки Институт Молекулярной Биологии Им. В.А. Энгельгардта Российской Академии Наук (Имб Ран) Рекомбинантный вектор для создания плазмидных генетических конструкций, обладающих повышенной длительностью экспрессии целевых генов
US20210343368A1 (en) * 2018-09-05 2021-11-04 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft Method for Engineering Synthetic Cis-Regulatory DNA
WO2020081537A1 (en) * 2018-10-16 2020-04-23 Texas Tech University System Method to express, purify, and biotinylate eukaryotic cell-derived major histocompatibility complexes
US20230193341A1 (en) 2018-10-24 2023-06-22 Selexis Sa Expression systems, recombinant cells and uses thereof
HUE068630T2 (hu) 2018-12-10 2025-01-28 Amgen Inc Mutáns PiggyBac transzpozáz
US12404527B2 (en) * 2018-12-24 2025-09-02 Selexs S.A. Characterization and inactivation of endogenous retroviruses in chinese hamster ovary cells
US20220088158A1 (en) 2019-01-23 2022-03-24 Aceragen, Inc. Method of ameliorating a pro-inflammatory immunophenotype in farber disease subjects by repeated administration of a recombinant human acid ceramidase
IT201900002321A1 (it) * 2019-02-18 2020-08-18 Univ Degli Studi Padova Peptidi con attivita' antitumorale
AU2020248453A1 (en) * 2019-03-27 2021-10-28 Phoenix Tissue Repair, Inc. Systems and methods for producing collagen 7 compositions
CN110006866B (zh) * 2019-04-16 2022-04-22 杭州迈尔德生物科技有限公司 一种阿片类活性物质的通用检测方法及其检测试剂盒
WO2020228721A1 (en) * 2019-05-13 2020-11-19 Lin Mei Chun Method and kit for monitoring cancer
EP4041895A1 (en) * 2019-10-10 2022-08-17 The Regents of the University of California Methods to stabilize mammalian cells
IL270306A (en) 2019-10-30 2021-05-31 Yeda Res & Dev Prevention and treatment of pre-myeloid and myeloid malignancies
CN112813099A (zh) * 2019-11-15 2021-05-18 上海细胞治疗集团有限公司 一种在活化的t细胞中具有高活性的启动子
CN110863008B (zh) * 2019-11-22 2020-10-16 昆明学院 Mar序列调控弱启动子构建高效表达载体的方法
US20230046668A1 (en) 2019-12-24 2023-02-16 Selexis S.A. Targeted integration in mammalian sequences enhancing gene expression
KR102937659B1 (ko) * 2020-02-19 2026-03-10 우시 바이올로직스 아일랜드 리미티드 강화된 발현 시스템 및 그 사용방법
CN111500629B (zh) * 2020-04-17 2021-11-19 安徽中盛溯源生物科技有限公司 一种高表达层粘连蛋白-511变体的方法及其应用
US20230242936A1 (en) * 2020-05-14 2023-08-03 Seattle Children's Hospital (dba Seattle Children's Research Institute) Dual promoter systems
US12173304B2 (en) * 2020-07-08 2024-12-24 Neuracle Genetics Inc. Intron fragments
CN113881703B (zh) * 2021-10-11 2022-06-21 中国人民解放军军事科学院军事医学研究院 一种提高cho细胞同源重组效率的方法及其相关产品和应用
CN116440269B (zh) * 2022-01-10 2024-02-09 华中农业大学 Slc35a1基因作为靶点在防治猪流行性腹泻病中的应用
CN114958914B (zh) * 2022-06-06 2023-09-26 新乡医学院 一种人类及哺乳动物细胞附着体表达载体、构建方法和应用
CN115896227A (zh) * 2022-12-20 2023-04-04 西北农林科技大学 一种鉴定外源基因整合位点以增强转基因表达的方法
GB202305637D0 (en) 2023-04-17 2023-05-31 Macomics Ltd Transposons, vectors and genetically engineered cells
GB202415693D0 (en) 2024-10-24 2024-12-11 Macomics Ltd Genetically-engineered cells

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731178A (en) 1990-03-21 1998-03-24 Behringwerke Aktiengesellschaft Attachment-elements for stimulation of eukaryotic expression systems
JP3656277B2 (ja) * 1995-05-17 2005-06-08 味の素株式会社 組換えdna法によるトランスグルタミナーゼの効率的製造法
DK1395669T3 (da) 2001-01-26 2009-11-16 Selexis Sa Matriks bindingsregioner og fremgangsmåder til anvendelse af disse
US20040235011A1 (en) * 2002-06-26 2004-11-25 Cooper Richard K. Production of multimeric proteins
WO2004065581A2 (en) * 2003-01-15 2004-08-05 Discovery Genomics, Inc. Transposon-insulator element delivery systems
US7244616B2 (en) * 2003-06-27 2007-07-17 Bayer Pharmaceuticals Corporation Use of molecular chaperones for the enhanced production of secreted, recombinant proteins in mammalian cells
KR101269656B1 (ko) 2003-10-24 2013-05-30 셀렉시스 에스. 에이. Mar 서열의 복합 트랜스펙션 방법에 의한 포유동물 세포에서의 고효율 유전자 전달 및 발현
ES2292271B1 (es) * 2004-05-20 2009-02-16 Proyecto De Biomedicina Cima, S.L. Un vector hibrido adenovirus-alfavirus para la administracion eficaz y expresion de genes terapeuticos en celulas tumorales.
WO2007021353A2 (en) * 2005-06-10 2007-02-22 Genentech, Inc. Improving antibody expression using vectors containing insulator elements
DK2205618T3 (en) 2007-09-26 2017-02-20 Intrexon Corp SYNTHETIC 5 'NON-TRANSLATED REGIONS, EXPRESSION VECTORS AND PROCEDURES FOR INCREASING TRANSGENIC EXPRESSION
US20090247609A1 (en) 2007-12-20 2009-10-01 Hitto Kaufmann Sm-protein based secretion engineering
WO2010008564A2 (en) * 2008-07-16 2010-01-21 Recombinetics Plaice dna transposon system
EP2417263B1 (en) * 2009-04-09 2015-09-23 ProteoVec Holding L.L.C. Production of proteins using transposon-based vectors
CN102575264A (zh) * 2009-09-18 2012-07-11 瑟莱克斯公司 增加的转基因表达和加工的产品和方法

Also Published As

Publication number Publication date
KR102235603B1 (ko) 2021-04-05
CN120718957A (zh) 2025-09-30
SG11201505487UA (en) 2015-08-28
HUE061494T2 (hu) 2023-07-28
CN105073995A (zh) 2015-11-18
RU2711505C2 (ru) 2020-01-17
WO2014118619A2 (en) 2014-08-07
HK1216323A1 (en) 2016-11-04
PL3536797T3 (pl) 2023-09-11
DK3536797T5 (da) 2024-09-02
EP2951309B1 (en) 2019-01-30
IL240198A0 (en) 2015-09-24
DK2951309T3 (en) 2019-04-23
JP6563816B2 (ja) 2019-08-21
EP3536797B1 (en) 2023-01-04
ZA201506419B (en) 2017-02-22
ES2717175T3 (es) 2019-06-19
AU2019250224A1 (en) 2019-11-07
EP3536797A1 (en) 2019-09-11
PT2951309T (pt) 2019-04-03
ES2940433T3 (es) 2023-05-08
AU2014210856B2 (en) 2019-10-24
RU2711505C9 (ru) 2020-08-12
CA2898878A1 (en) 2014-08-07
US20150361451A1 (en) 2015-12-17
DK3536797T3 (da) 2023-04-03
AU2019250224B2 (en) 2022-05-12
CA2898878C (en) 2020-04-28
AU2014210856A1 (en) 2015-07-30
EP2951309A2 (en) 2015-12-09
PL2951309T3 (pl) 2019-06-28
WO2014118619A3 (en) 2014-10-30
SG10201803758XA (en) 2018-06-28
RU2015127667A (ru) 2017-03-06
HUE043103T2 (hu) 2019-08-28
IL240198B (en) 2019-10-31
KR20150123803A (ko) 2015-11-04
SI2951309T1 (sl) 2019-04-30
LT2951309T (lt) 2019-03-25
JP2016504922A (ja) 2016-02-18
US11898154B2 (en) 2024-02-13
PT3536797T (pt) 2023-03-15

Similar Documents

Publication Publication Date Title
PH12020551039A1 (en) Non-viral dna vectors and uses thereof for antibody and fusion protein production
JP2016504922A5 (enExample)
NZ609903A (en) Expression vector for high level expression of recombinant proteins
HRP20190970T1 (hr) Polipeptidi koji sadrže neglikozilirani fc
PE20251181A1 (es) Agentes potenciadores para la transfeccion celular mejorada y/o la produccion del vector raav
PH12015501837B1 (en) Manufacturing methods to control c-terminal lysine, galactose and sialic acid content in recombinant proteins
WO2009091912A3 (en) Improved mammalian expression vectors and uses thereof
NO20076087L (no) Serum-fri stabil transfeksjon og fremstilling av rekombinante humane proteiner i humane cellelinjer
Gantz et al. Targeted genomic integration of a selectable floxed dual fluorescence reporter in human embryonic stem cells
BRPI0612273A2 (pt) anticorpo de ligaÇço a il-1 beta ou fragmento de ligaÇço a il-1 beta do mesmo, Ácido nucleico, vetor, cÉlula, animal transgÊnico, hibridoma, composiÇço, e, mÉtodos de tratamento ou prevenÇço de uma doenÇa ou doenÇa relacionada a il-1 em um mamÍfero, e de preparaÇço de um polipeptÍdeo de ligaÇço a il-1 beta maturado por afinidade
EA201170993A1 (ru) Удлиненные рекомбинантные полипептиды и содержащие их композиции
EA201492202A1 (ru) Способ экспрессии гетерологичных белков с использованием рекомбинантного вирусного вектора с минус-нитью рнк
Jordan et al. Expression of green fluorescent protein in the chicken using in vivo transfection of the piggyBac transposon
EP2589658A4 (en) PARTICLE POLYPEPTIDE OF THE REIC / DKK-3 PROTEIN
Fenno et al. A guide to creating and testing new INTRSECT constructs
Zhang et al. The activation of antiviral RNA interference not only exists in neural progenitor cells but also in somatic cells in mammals
CN104350068B (zh) 生产型细胞系的增强子
JP2017524366A5 (enExample)
KR20260034618A (ko) 털매머드 특이적 유전자 변이체 및 이를 포함하는 조성물
WO2013052814A8 (en) E1 enzyme mutants and uses thereof
EA201690634A1 (ru) Новая гетеро-трансгликозилаза и ее применение
EA201391444A1 (ru) Вариант инсектицидного гена axmiи способы его применения
CN103421793B (zh) 猪肝脏特异性表达基因ttr启动子的克隆及应用
SG163592A1 (en) Methods and compositions for increasing longevity and protein yield from a cell culture
Min et al. Generation of antiviral transgenic chicken using spermatogonial stem cell transfected in vivo